Please note that only limited free access to this journal is available in your country or territory.

To access the full content of this article you must purchase it (US$9.49). After payment of this one-off fee, you will gain unrestricted online access to the article and a PDF version sent to your email.

As part of our special introductory offer, after purchasing this article you will have unrestricted access to all the articles in this issue for free!

Registered users can purchase/access the article by logging in below. To register for free click here

Registered users login here:

  • Email Address:
     
  • Password:
     
  •  
If you have forgotten your password click here
1 ratings / 5 average

Treating Rheumatoid Arthritis to Target: Background and Prospects


Josef S Smolen, MD, FRCP, and Daniel Aletaha, MD, MS

Among the chronic inflammatory rheumatic diseases, rheumatoid arthritis (RA) is not only the most frequent, affecting 0.5–1% of the population, but is also the one with the highest propensity for joint destruction. Even at the first visit of patients with early arthritis of <3 months’ symptom duration, approximately 10% can have radiographically visible signs of joint damage [1]; furthermore, within the first 2 years, evidence of joint destruction can be found in up to 70% of patients, sometimes affecting >50% of the maximally involved joints [2–4].

Please login or register to continue reading this article
Return to top
Login/Register

Post Page On

LATEST ARTICLES

Our most popular articles